Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6467313 | 0.90 | ITK (0.41) | ITKIRAK4PARP1SMN1; SMN2LMNA | |
| SCHEMBL6466381 | 0.80 | ITK (0.42) | ITKSCN9AIRAK4PARP1SMN1; SMN2 | |
| SCHEMBL6506661 | 0.80 | ITK (0.48) | ITKSCN9AIRAK4PARP1RIPK1 | |
| SCHEMBL6499383 | 0.78 | MAPT (0.39) | ITKIRAK4SMN1; SMN2LMNAKMT2A | |
| SCHEMBL6503646 | 0.78 | ITK (0.51) | ITKSCN9AIRAK4SMN1; SMN2LMNA | |
| SCHEMBL6501636 | 0.77 | SCN9A (0.45) | ITKSCN9AIRAK4SMN1; SMN2LMNA | |
| SCHEMBL6505234 | 0.77 | ITK (0.49) | ITKSCN9AIRAK4PARP1SMN1; SMN2 | |
| SCHEMBL6468751 | 0.77 | ITK (0.44) | ITKSCN9AIRAK4PARP1LMNA | |
| SCHEMBL6468080 | 0.76 | ITK (0.42) | ITKSCN9AIRAK4PARP1SMN1; SMN2 | |
| SCHEMBL6501657 | 0.76 | ITK (0.44) | ITKSCN9AIRAK4SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | ITK 4236/4885SCN9A 4159/4885IRAK4 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.